Compare
Electromed, Inc. vs Ceribell, Inc. vs Biolife Solutions Inc vs Iridex Corp
| Latest fiscal year | Electromed, Inc. ELMD | Ceribell, Inc. CBLL | Biolife Solutions Inc BLFS | Iridex Corp IRIX |
|---|---|---|---|---|
| Year ended | 2026-06-30 | 2025-12-31 | 2025-12-31 | 2026-01-03 |
| Revenue | $73.78M | $89.06M | $96.21M | $52.67M |
| Revenue growth (YoY) | +15.3% | +36.1% | +28.9% | +8.2% |
| Gross margin | 78.5% | 87.9% | 64.6% | 36.5% |
| Operating margin | 18.8% | -65.6% | -17.3% | -4.9% |
| Net margin | 15.3% | -60.0% | -4.8% | -8.4% |
| Net income | $11.30M | -$53.41M | -$4.59M | -$4.44M |
| EPS (Diluted) | $1.30 | -$1.46 | -$0.10 | -$0.26 |
| Operating cash flow | $9.66M | -$40.81M | $20.11M | -$2.12M |
| Free cash flow | $8.41M | -$41.58M | $10.64M | -$2.26M |
| Cash & equivalents | $20.45M | $40.48M | $33.04M | $6.03M |
| Total assets | $66.27M | $195.80M | $405.88M | $29.15M |
| Total liabilities | $12.29M | $40.47M | $34.00M | $24.23M |
| Shareholders' equity | $53.98M | $155.34M | $371.89M | $4.92M |
| Return on year-end equity | 20.9% | -34.4% | -1.2% | -90.1% |
| Shares outstanding | 8.37M | 37.49M | 48.20M | 17.31M |
Revenue, most recent five fiscal years
| Fiscal year | Electromed, Inc. | Ceribell, Inc. | Biolife Solutions Inc | Iridex Corp |
|---|---|---|---|---|
| Latest | $73.78M Ended 2026-06-30 | $89.06M Ended 2025-12-31 | $96.21M Ended 2025-12-31 | $52.67M Ended 2026-01-03 |
| 1 year earlier | $64.00M Ended 2025-06-30 | $65.44M Ended 2024-12-31 | $74.65M Ended 2024-12-31 | $48.67M Ended 2024-12-28 |
| 2 years earlier | $54.72M Ended 2024-06-30 | $45.23M Ended 2023-12-31 | $68.02M Ended 2023-12-31 | $51.87M Ended 2023-12-30 |
| 3 years earlier | $48.07M Ended 2023-06-30 | n/a | $76.24M Ended 2022-12-31 | $56.97M Ended 2022-12-31 |
| 4 years earlier | $41.66M Ended 2022-06-30 | n/a | $119.16M Ended 2021-12-31 | $53.90M Ended 2022-01-01 |